Histone deacetylases in vascular permeability and remodeling associated with acute lung injury

Abstract

Acute lung injury (ALI) is a severe progressive disorder that arises from a wide range of causes such as toxins or inflammation, resulting in significant morbidity and mortality. There are no effective therapeutic options apart from mechanical ventilation strategies. While the mechanisms that govern the clinically relevant process of increased endothelial cell (EC) permeability and remodeling associated with ALI are under intense investigation, our knowledge of the processes that determine barrier enhancement or preservation are far from completion. Recently, epigenetic mechanisms have emerged as a major regulator of enduring changes in cell behavior and the therapeutic potential of inhibiting histone deacetylases (HDACs) for the treatment of cardiovascular and inflammatory diseases has gained remarkable attention. Although HDACs have been shown to play an important role in regulating EC barrier function, the involved HDAC subtypes and mechanisms remain undefined. Further investigation of the HDAC signaling may provide therapeutic approaches for the prevention and treatment of ALI.

Keywords

Acute lung injury / endothelial barrier function / histone deacetylases

References

[1] Johnson ER.Acute lung injury: epidemiology, pathogenesis, and treatment.J Aerosol Med Pulm Drug Deliv2010;23:243-52 PMCID:PMC3133560

[2] Rubenfeld GD,Peabody E,Martin DP,Stern EJ.Incidence and outcomes of acute lung injury.N Engl J Med2005;353:1685-93

[3] Butt Y,Allen TC.Acute lung injury: a clinical and molecular review.Arch Pathol Lab Med2016;140:345-50

[4] Parekh D,Thickett DR.Acute lung injury.Clin Med (Lond)2011;11:615-8

[5] Gonzales JN,Verin AD.The acute respiratory distress syndrome: mechanisms and perspective therapeutic approaches.Austin J Vasc Med2015;2:1009 PMCID:PMC4786180

[6] Maniatis NA,Catravas JD.Endothelial pathomechanisms in acute lung injury.Vascul Pharmacol2008;49:119-33

[7] Lucas R,Black SM.Regulators of endothelial and epithelial barrier integrity and function in acute lung injury.Biochem Pharmacol2009;77:1763-72 PMCID:PMC4474367

[8] Bazzoni G.Endothelial cell-to-cell junctions: molecular organization and role in vascular homeostasis.Physiol Rev2004;84:869-901

[9] Kasa A,Verin AD.Cytoskeletal mechanisms regulating vascular endothelial barrier function in response to acute lung injury.Tissue Barriers2015;3:e974448 PMCID:PMC4372017

[10] Jeffries MA.Autoimmune disease in the epigenetic era: how has epigenetics changed our understanding of disease and how can we expect the field to evolve?.Expert Rev Clin Immunol2015;11:45-58 PMCID:PMC4636192

[11] Greer JM.The role of epigenetic mechanisms and processes in autoimmune disorders.Biologics2012;6:307-27

[12] Struhl K.Histone acetylation and transcriptional regulatory mechanisms.Genes Dev1998;12:599-606

[13] Kuo MH.Roles of histone acetyltransferases and deacetylases in gene regulation.Bioessays1998;20:615-26

[14] Glozak MA.Histone deacetylases and cancer.Oncogene2007;26:5420-32

[15] Halili MA,Sweet MJ.Histone deacetylase inhibitors in inflammatory disease.Curr Top Med Chem2009;9:309-19

[16] Ito K,Adcock IM.Glucocorticoid receptor recruitment of histone deacetylase 2 inhibits interleukin-1beta-induced histone H4 acetylation on lysines 8 and 12.Mol Cell Biol2000;20:6891-903 PMCID:PMC88765

[17] Yang XJ.Lysine acetylation: codified crosstalk with other posttranslational modifications.Mol Cell2008;31:449-61 PMCID:PMC2551738

[18] Peng L,Seto E.Histone deacetylase activity assay.Methods Mol Biol2015;1288:95-108

[19] Saito S,Guo W,Mai A,Sullivan DE.Pharmacological inhibition of HDAC6 attenuates endothelial barrier dysfunction induced by thrombin.Biochem Biophys Res Commun2011;408:630-4 PMCID:PMC3100403

[20] Joshi AD,Birmpas C,Thangjam G,Dennison J.Histone deacetylase inhibitors prevent pulmonary endothelial hyperpermeability and acute lung injury by regulating heat shock protein 90 function.Am J Physiol Lung Cell Mol Physiol2015;309:L1410-9 PMCID:PMC4683315

[21] Seto E.Erasers of histone acetylation: the histone deacetylase enzymes.Cold Spring Harb Perspect Biol2014;6:a018713 PMCID:PMC3970420

[22] de Ruijter AJ,Caron HN,van Kuilenburg AB.Histone deacetylases (HDACs): characterization of the classical HDAC family.Biochem J2003;370:737-49 PMCID:PMC1223209

[23] Dali-Youcef N,Froelich S,Schoonjans K.Sirtuins: the 'magnificent seven', function, metabolism and longevity.Ann Med2007;39:335-45

[24] Sengupta N.Regulation of histone deacetylase activities.J Cell Biochem2004;93:57-67

[25] Bjerling P,Thon G,Grewal S.Functional divergence between histone deacetylases in fission yeast by distinct cellular localization and in vivo specificity.Mol Cell Biol2002;22:2170-81 PMCID:PMC133699

[26] Johnstone RW.Histone-deacetylase inhibitors: novel drugs for the treatment of cancer.Nat Rev Drug Discov2002;1:287-99

[27] Yang WM,Wen YD,Seto E.Functional domains of histone deacetylase-3.J Biol Chem2002;277:9447-54

[28] Van den Wyngaert I,Kremer A,Verhasselt P,Kass SU.Cloning and characterization of human histone deacetylase 8.FEBS Lett2000;478:77-83

[29] Yang XJ.The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men.Nat Rev Mol Cell Biol2008;9:206-18 PMCID:PMC2667380

[30] Watson PJ,Riley AM,Wright LC,Cowley SM,Potter BV.Insights into the activation mechanism of class I HDAC complexes by inositol phosphates.Nat Commun2016;7:11262 PMCID:PMC4848466

[31] Verdin E,Kasler HG.Class II histone deacetylases: versatile regulators.Trends Genet2003;19:286-93

[32] Bertos NR,Yang XJ.Class II histone deacetylases: structure, function, and regulation.Biochem Cell Biol2001;79:243-52

[33] Parra M.Regulatory signal transduction pathways for class IIa histone deacetylases.Curr Opin Pharmacol2010;10:454-60

[34] Valenzuela-Fernandez A,Serrador JM.HDAC6: a key regulator of cytoskeleton, cell migration and cell-cell interactions.Trends Cell Biol2008;18:291-7

[35] Guardiola AR.Molecular cloning and characterization of a novel histone deacetylase HDAC10.J Biol Chem2002;277:3350-6

[36] Gao L,Asselbergs F.Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family.J Biol Chem2002;277:25748-55

[37] Frye RA.Phylogenetic classification of prokaryotic and eukaryotic Sir2-like proteins.Biochem Biophys Res Commun2000;273:793-8

[38] Haigis MC.Mammalian sirtuins--emerging roles in physiology, aging, and calorie restriction.Genes Dev2006;20:2913-21

[39] Min J,Sternglanz R.Crystal structure of a SIR2 homolog-NAD complex.Cell2001;105:269-79

[40] Denu JM.The Sir 2 family of protein deacetylases.Curr Opin Chem Biol2005;9:431-40

[41] Frye RA.Characterization of five human cDNAs with homology to the yeast SIR2 gene: Sir2-like proteins (sirtuins) metabolize NAD and may have protein ADP-ribosyltransferase activity.Biochem Biophys Res Commun1999;260:273-9

[42] Drazic A,Ree R.The world of protein acetylation.Biochim Biophys Acta2016;1864:1372-401

[43] Jenuwein T.Translating the histone code.Science2001;293:1074-80

[44] Ruthenburg AJ,Patel DJ.Multivalent engagement of chromatin modifications by linked binding modules.Nat Rev Mol Cell Biol2007;8:983-94 PMCID:PMC4690530

[45] Wang Z,Cui K,Barski A,Zhao K.Genome-wide mapping of HATs and HDACs reveals distinct functions in active and inactive genes.Cell2009;138:1019-31 PMCID:PMC2750862

[46] Spange S,Heinzel T.Acetylation of non-histone proteins modulates cellular signalling at multiple levels.Int J Biochem Cell Biol2009;41:185-98

[47] Caron C,Khochbin S.Regulatory cross-talk between lysine acetylation and ubiquitination: role in the control of protein stability.Bioessays2005;27:408-15

[48] Haberland M,Olson EN.The many roles of histone deacetylases in development and physiology: implications for disease and therapy.Nat Rev Genet2009;10:32-42 PMCID:PMC3215088

[49] Bassett SA.The role of dietary histone deacetylases (HDACs) inhibitors in health and disease.Nutrients2014;6:4273-301 PMCID:PMC4210916

[50] Lawless MW,O'Byrne KJ.Targeting histone deacetylases for the treatment of disease.J Cell Mol Med2009;13:826-52 PMCID:PMC3823402

[51] Tang J,Zhuang S.Histone deacetylases as targets for treatment of multiple diseases.Clin Sci (Lond)2013;124:651-62 PMCID:PMC4568123

[52] Pan LN,Huang B.HDAC inhibitors: a potential new category of anti-tumor agents.Cell Mol Immunol2007;4:337-43

[53] Walkinshaw DR.Histone deacetylase inhibitors as novel anticancer therapeutics.Curr Oncol2008;15:237-43 PMCID:PMC2582508

[54] Adcock IM.HDAC inhibitors as anti-inflammatory agents.Br J Pharmacol2007;150:829-31 PMCID:PMC2013887

[55] Leoni F,Bertolini G,Pagani P,Dona G,Sozzani S,Bufler P,Goncharov I,Pomerantz BJ,Siegmund B,Mascagni P.The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines.Proc Natl Acad Sci U S A2002;99:2995-3000 PMCID:PMC122461

[56] Ito K,Elliott WM,Caramori G,Barczyk A,Adcock IM,Barnes PJ.Decreased histone deacetylase activity in chronic obstructive pulmonary disease.N Engl J Med2005;352:1967-76

[57] Ito K,Adcock IM.Impact of protein acetylation in inflammatory lung diseases.Pharmacol Ther2007;116:249-65

[58] Adcock IM,Barnes PJ.Histone deacetylation: an important mechanism in inflammatory lung diseases.COPD2005;2:445-55

[59] Chong DL.Pro-inflammatory mechanisms in sepsis.Contrib Microbiol2011;17:86-107

[60] Aird WC.The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome.Blood2003;101:3765-77

[61] Yu J,Shetty S,Fu J.Selective HDAC6 inhibition prevents TNF-alpha-induced lung endothelial cell barrier disruption and endotoxin-induced pulmonary edema.Am J Physiol Lung Cell Mol Physiol2016;311:L39-47

[62] Yu J,Ma Z.HDAC6 inhibition prevents TNF-alpha-induced caspase 3 activation in lung endothelial cell and maintains cell-cell junctions.Oncotarget2016;7:54714-22 PMCID:PMC5342375

[63] Ni YF,Yan XL,Zhao JB,Jiang T.Histone deacetylase inhibitor, butyrate, attenuates lipopolysaccharide-induced acute lung injury in mice.Respir Res2010;11:33 PMCID:PMC2848144

[64] Zhang L,Wang C,Wan J.Histone deacetylase inhibitors attenuate acute lung injury during cecal ligation and puncture-induced polymicrobial sepsis.World J Surg2010;34:1676-83

[65] Kasotakis G,Osathanugrah P,Bufe L,Mizgerd JP.Timing of valproic acid in acute lung injury: prevention is the best therapy?.J Surg Res2017;220:206-12

[66] Kasotakis G,King E,Stucchi A,Burke PA.Valproic acid mitigates the inflammatory response and prevents acute respiratory distress syndrome in a murine model of Escherichia coli pneumonia at the expense of bacterial clearance.J Trauma Acute Care Surg2017;82:758-65 PMCID:PMC5360476

[67] Wu SY,Ko FC,Huang KL.Valproic acid attenuates acute lung injury induced by ischemia-reperfusion in rats.Anesthesiology2015;122:1327-37

[68] Lu W,Ouyang P,Wu D,Wu Z,Xu Z,Zou S,Li J,Lin P,Huang J.Drug repurposing of histone deacetylase inhibitors that alleviate neutrophilic inflammation in acute lung injury and idiopathic pulmonary fibrosis via inhibiting leukotriene A4 hydrolase and blocking LTB4 biosynthesis.J Med Chem2017;60:1817-28

[69] Lu Q,Grinnell K,Ortiz M,Sanchez-Esteban J,Rounds S.Cigarette smoke causes lung vascular barrier dysfunction via oxidative stress-mediated inhibition of RhoA and focal adhesion kinase.Am J Physiol Lung Cell Mol Physiol2011;301:L847-57 PMCID:PMC3233834

[70] Borgas D,Newton J,Rivera S,Lu Q.Cigarette smoke disrupted lung endothelial barrier integrity and increased susceptibility to acute lung injury via histone deacetylase 6.Am J Respir Cell Mol Biol2016;54:683-96 PMCID:PMC4942194